New hope for bladder cancer patients who can't have standard chemo

NCT ID NCT06263153

Recruiting now Disease control Sponsor: Yuanquan Yang Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests two drugs, futibatinib and durvalumab, given before surgery to remove the bladder in people with muscle-invasive bladder cancer who cannot take standard chemotherapy. The goal is to see if this combination can eliminate or shrink the cancer enough to improve outcomes. About 24 adults with specific genetic markers will participate.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER UROTHELIAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bladder transitional cell carcinoma infiltrating bladder urothelial carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLADDER UROTHELIAL CARCINOMA MUSCLE-INVASIVE BLADDER CARCINOMA STAGE II BLADDER CANCER AJCC V8 STAGE IIIA BLADDER CANCER AJCC V8

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Cleveland Clinic Taussig Cancer Center
RECRUITING

Cleveland, Ohio, 44195, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Ohio State University Comprehensive Cancer Center
RECRUITING

Columbus, Ohio, 43210, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
University of Michigan Comprehensive Cancer Center
WITHDRAWN

Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.